DHG Pharmaceutical JSC (HOSE: DHG)

DHG Pharmaceutical JSC Income Statement

Financials in millions VND. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	4,960,915	5,015,395	4,676,016	4,003,170	3,755,619	3,896,754
Revenue Growth (YoY)	3.12%	7.26%	16.81%	6.59%	-3.62%	0.38%
Cost of Revenue	2,836,449	2,671,850	2,418,521	2,082,260	1,944,243	2,184,462
Gross Profit	2,124,466	2,343,545	2,257,495	1,920,911	1,811,376	1,712,292
Selling, General & Admin	1,257,799	1,291,264	1,181,417	1,060,127	1,002,160	1,020,875
Operating Expenses	1,257,799	1,291,264	1,181,417	1,060,127	1,002,160	1,020,875
Operating Income	866,667	1,052,281	1,076,078	860,784	809,216	691,417
Interest Expense	-24,303	-29,530	-12,559	-12,080	-14,030	-22,715
Interest & Investment Income	152,214	202,173	120,337	114,306	133,858	768
Earnings From Equity Investments	-	-	-	-	-500.64	-112.63
Currency Exchange Gain (Loss)	3,150	5,580	3,587	4,160	-2,966	-2,132
Other Non Operating Income (Expenses)	-70,838	-73,082	-89,517	-93,955	-84,764	39,566
EBT Excluding Unusual Items	926,891	1,157,423	1,097,926	873,214	840,814	706,791
Gain (Loss) on Sale of Investments	315	315	-772.55	274.7	-14,605	3,015
Gain (Loss) on Sale of Assets	1,708	1,437	2,518	-7,999	3,264	7,065
Asset Writedown	-	-	-	-	-3,011	-3,677
Other Unusual Items	-	-	-58.33	-1,488	-5,438	-
Pretax Income	928,914	1,159,174	1,099,613	864,002	821,024	713,195
Income Tax Expense	97,897	108,512	111,159	87,717	82,490	81,932
Earnings From Continuing Operations	831,016	1,050,663	988,455	776,285	738,534	631,263
Minority Interest in Earnings	-	-	-	934.93	1,341	4,125
Net Income	831,016	1,050,663	988,455	777,220	739,875	635,388
Preferred Dividends & Other Adjustments	26,930	33,520	31,654	29,317	28,196	25,062
Net Income to Common	804,086	1,017,143	956,801	747,903	711,679	610,326
Net Income Growth	-19.05%	6.29%	27.18%	5.05%	16.44%	-2.70%
Shares Outstanding (Basic)	131	131	131	131	131	131
Shares Outstanding (Diluted)	131	131	131	131	131	131
EPS (Basic)	6149.98	7779.53	7318.01	5720.27	5443.21	4668.03
EPS (Diluted)	6149.98	7779.53	7318.01	5720.27	5443.21	4668.03
EPS Growth	-19.09%	6.31%	27.93%	5.09%	16.61%	4.88%
Free Cash Flow	842,908	-246,171	667,293	427,882	737,369	781,139
Free Cash Flow Per Share	6446.91	-1882.82	5103.73	3272.62	5639.70	5974.47
Dividend Per Share	3500.000	7500.000	3500.000	3500.000	4000.000	4000.000
Dividend Growth	-53.33%	114.29%	0%	-12.50%	0%	14.29%
Gross Margin	42.82%	46.73%	48.28%	47.98%	48.23%	43.94%
Operating Margin	17.47%	20.98%	23.01%	21.50%	21.55%	17.74%
Profit Margin	16.21%	20.28%	20.46%	18.68%	18.95%	15.66%
Free Cash Flow Margin	16.99%	-4.91%	14.27%	10.69%	19.63%	20.05%
EBITDA	972,802	1,140,001	1,157,079	943,348	897,413	780,128
EBITDA Margin	19.61%	22.73%	24.74%	23.57%	23.90%	20.02%
D&A For EBITDA	106,135	87,720	81,001	82,564	88,197	88,711
EBIT	866,667	1,052,281	1,076,078	860,784	809,216	691,417
EBIT Margin	17.47%	20.98%	23.01%	21.50%	21.55%	17.74%
Effective Tax Rate	10.54%	9.36%	10.11%	10.15%	10.05%	11.49%
Revenue as Reported	4,960,915	5,015,395	4,676,016	4,003,170	3,755,619	3,896,754
Advertising Expenses	-	128,162	138,011	138,095	119,136	115,787

Source: S&P Capital IQ. Standard template. Financial Sources.